相关实验视频

Updated: Jan 17, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

对新型2-基-1,4-纳夫托金二醇衍生物的抗癌作用的机制见解

Thaís Barreto Santos¹, Alex de Souza Cruz Lopes Canuto², João Francisco Blaudt Virgilio de Carvalho Meira³

¹Institute of Chemistry,Universidade Federal Fluminense, Niterói, Rio de Janeiro 24020-141, Brazil.

|September 22, 2025

概括

新的 thionaphthoquinone衍生物显示出作为口腔癌治疗的前景. 在临床前模型中,化合物7a和7e对口腔状细胞癌 (SCC) 具有显著的细胞毒性,具有高选择性和低毒性.

科学领域:

药用化学医学化学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

口腔癌,主要是状细胞癌 (SCC),是全球主要的健康问题.
目前用于SCC的治疗方法存在局限性和不良影响,需要新的治疗策略.
纳夫托基诺具有多种药理性质,包括抗癌潜力.

研究的目的:

合成和评估新型纳弗托金衍生物对它们对口腔SCC细胞系的细胞毒性活性.
在各种癌症模型和动物研究中评估有前途的化合物的选择性和安全性.
研究化合物的作用机制并预测化合物的药理动力学特性.

主要方法:

合成十个α-xyloidone和醇衍生型的 thionaphthoquinone 化合物.
对口腔SCC细胞系 (SCC-4,SCC-9,SCC-25) 和其他癌细胞系 (HCT-116,HepG2,B16-F10) 的细胞毒性测定.
细胞膜完整性,细胞亡和自分析,细胞迁移测定, *in silico* 药物动力学预测和分子对接研究.

主要成果:

两个化合物,7a和7e对所有测试的口服SCC细胞系表现出显著的选择性 (SI>2).
化合物7a和7e在结直肠,肝脏和黑色素瘤癌症模型中显示出高选择性.
对于7a和7e,在小鼠中观察到最小的膜破裂 (<2%) 和没有急性毒性.
细胞灭亡和自被确定为细胞死亡的机制,有效抑制细胞迁移.
*in silico*分析预测了这两种化合物的口服生物可用性和低毒性,其中7e向RSK2和拓酶等关键酶.

结论:

纳丁素7a和7e对口服SCC具有强烈的细胞毒性作用,具有良好的安全性.
这些化合物显示出作为开发新型口腔癌疗法的主要候选人的前景.
需要进一步研究它们的治疗潜力和作用机制.

更多相关视频

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

A Direct, Regioselective and Atom-Economical Synthesis of 3-Aroyl-N-hydroxy-5-nitroindoles by Cycloaddition of 4-Nitronitrosobenzene with Alkynones

Published on: January 21, 2020

相关概念视频

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...